SecBot SecBot
SECBOTREPLAY Home › Report › IRON

IRON · Disc Medicine reported a significant increase in net loss to $212.2…

Disc Medicine, Inc. · 8-K filed Feb 26, 2026 at 08:32 ET

At the news

BEARISHIMPACT 7/10

8-K filed Feb 26, 2026 at 08:32 ET

Disc Medicine reported a significant increase in net loss to $212.2 million in 2025, primarily due to higher R&D and SG&A expenses. Despite receiving a Complete Response Letter (CRL) from the FDA for bitopertin, the company maintains a strong cash position of $791.2 million, providing runway into 2029. The company is advancing its pipeline with positive data from DISC-0974 in myelofibrosis and progressing other clinical trials.

  • Net loss increased to $212.2 million in 2025 from $109.4 million in 2024
  • Received Complete Response Letter (CRL) from FDA for bitopertin in EPP
  • Cash position is $791.2 million, providing runway into 2029
  • R&D expenses increased to $170.6 million from $96.7 million

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access